Center for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, UK.
Curr Mol Med. 2011 Nov;11(8):686-95. doi: 10.2174/156652411797536688.
The identification of a relevant effector of Ran GTPase (Ran) signaling and its pathways could provide a novel approach to cancer therapeutics. With recent research highlighting the significant relationship between Ran expression and the occurrence and progression of cancer, the development of a small molecule compound that would decrease the endogenous levels of Ran in the cell would have anti-mitotic effects and could lead to the development of new types of cancer therapeutics. In the absence of Ran binding proteins, Ran is expected to remain locked up in non-productive complexes with importins and is effectively removed from the system. Thus, Ran binding proteins present as a logical molecular target for the inhibition of Ran signaling within the cancer cell. Moreover, this family of proteins has been shown to have various other functions within the cell, some of which are also anti-neoplastic. The purpose of this review is to discuss Ran binding proteins and how their pathways may be exploited to provide an effective cancer treatment.
鉴定 Ran GTPase(Ran)信号及其途径的相关效应子,可以为癌症治疗提供新方法。最近的研究强调了 Ran 表达与癌症发生和进展之间的显著关系,因此开发一种能够降低细胞内内源 Ran 水平的小分子化合物将具有抗有丝分裂作用,并可能导致开发新型癌症治疗方法。在没有 Ran 结合蛋白的情况下,Ran 预计将与导入蛋白保持在非生产性复合物中,并从系统中有效去除。因此,Ran 结合蛋白是抑制癌细胞中 Ran 信号的逻辑分子靶标。此外,该蛋白家族已被证明在细胞内具有多种其他功能,其中一些功能也具有抗肿瘤作用。本文综述的目的是讨论 Ran 结合蛋白及其途径如何被利用以提供有效的癌症治疗。